# Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct07161791/  
OnCo record `nct07161791` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by Harbin Medical University, not yet recruiting.

## Summary

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer is a phase 1/2, interventional study registered as NCT07161791 by Harbin Medical University, with a registry enrolment figure of 12 participants, started 2025-09-15 and due to reach its primary completion in 2026-12-31. Interventions recorded: Camrelizumab Combined With Pirfenidone and Chemotherapy. Conditions listed: Breast Cancer; Triple Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "* Histologically confirmed recurrent/metastatic TNBC (ER-negative: IHC ER \<1%; PR-negative: IHC PR \<1%; HER2-negative: IHC -/+, or IHC ++ but FISH/CISH negative), with at least one measurable lesion per RECIST v1". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07161791
- Phase: 1/2
- Setting: Exploratory Clinical Study of Camrelizumab Combined With Pirfenidone and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
- Sponsor: Harbin Medical University
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT07161791: https://clinicaltrials.gov/study/NCT07161791

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07161791.json